Stocks Health care NVCR

NASDAQ · Health care

NovoCure Ltd (NVCR)

NovoCure Ltd brought in $699.2M of revenue over the twelve months to June 30, 2026, up 11.0% from a year earlier. It posted a net loss of $148.6M. In fiscal 2025 capital spending exceeded operating cash flow by $75.7M. At June 30, 2026 it held $93.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.

What NovoCure Ltd does

NovoCure Ltd is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NVCR.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where NVCR ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What NovoCure Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 9, 2026
   Executive or director change 8-K
2. September 1, 2026
   Other event 8-K
3. July 23, 2026
   Quarterly results 8-K
4. July 23, 2026
   Quarterly report 10-Q · period to June 30, 2026
5. June 30, 2026
   Investor disclosure 8-K
6. June 18, 2026
   Investor disclosure 8-K
7. June 5, 2026
   Executive or director change 8-K
8. May 21, 2026
   Additional proxy material DEFA14A
9. May 8, 2026
   Passive stake changed SCHEDULE 13G/A
10. April 30, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 23, 2026. Insider transactions on SEC

Insider trades

What the people running NovoCure Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about NVCR

What does NovoCure Ltd do?

NovoCure Ltd is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NVCR.

Is NovoCure Ltd profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $148.6M on revenue of $699.2M.

How much revenue does NovoCure Ltd make?

Over the twelve months to June 30, 2026 NovoCure Ltd reported revenue of $699.2M. That is 11.0% more than a year earlier.

When did NovoCure Ltd last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 9, 2026.

Similar companies

Compare NVCR with

Compare NVCR with any company

Follow NVCR

Get an email when NovoCure Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow NVCR: get an email when it files

Where the numbers come from

Financial figures are the values NovoCure Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.